Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, is the development of cancer from the colon or rectum (parts of the large intestine). [5] Signs and symptoms may include blood in the stool, a change in bowel movements, weight loss, abdominal pain and fatigue. [9]

Most colorectal cancers start as a growth on the inner lining of the colon or rectum. These growths are called polyps. Polyps are quite common, especially as you get older. Most polyps are benign, or noncancerous. Some types of polyps can change into …

2020年3月20日 · Colorectal cancer (CRC) is among the most lethal and prevalent malignancies in the world and was responsible for nearly 881,000 cancer-related deaths in 2018....

2024年8月15日 · Colorectal cancer (CRC) is among the most common malignancies. Extensive bulk-level studies have characterized the molecular landscapes of CRC 1, 2, 3 and established four...

Colorectal cancer (CRC), which comprises colon and/or rectum cancer, represents a significant health problem as the world’s third most commonly diagnosed and second most fatal cancer globally [1]. Approximately 9.4% of cancer-related deaths were due to CRC in 2020 [2].

2015年11月1日 · Adenocarcinoma of the colon and rectum (colorectal cancer, CRC) is the third most common cancer, the fourth most common cause of cancer death, and the second most common cancer in terms of the number of individuals …

2024年10月7日 · We discuss the molecular hallmarks of CRC, including the genomic, epigenomic and microbial features of CRC to highlight the role of signal transduction in the orchestration of the tumorigenic...

Colorectal cancer (CRC) is a malignant tumor in the digestive system whose incidence and mortality is high-ranking among tumors worldwide. The initiation and progression of CRC is a complex process involving genetic alterations in cancer cells and ...

2025年1月13日 · Chimeric antigen receptor-T (CAR-T) cell therapy, initially successful in hematologic malignancies, presents a promising avenue for treating solid tumors, including CRC. This review explores the potential of CAR-T cell therapy in CRC by analyzing clinical trials and highlighting prominent CRC-specific targets.

Colorectal cancer (CRC) has the third highest incidence of all types of cancer worldwide, but the second highest mortality rate, with more than 1 million cases diagnosed and half a million deaths each year (1). The prognosis of CRC is related to the stage at the time of diagnosis.